Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 89

Results For "FY"

2306 News Found

STADA & Bio-Thera bag European nod for Gotenfia
Drug Approval | February 16, 2026

STADA & Bio-Thera bag European nod for Gotenfia


Agilent’s PD-L1 test gains FDA nod for ovarian cancer
News | February 16, 2026

Agilent’s PD-L1 test gains FDA nod for ovarian cancer

This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA


FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue
Drug Approval | February 14, 2026

FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue

The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”


DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains
Sustainability | February 13, 2026

DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains

The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio


Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%
News | February 11, 2026

Wockhardt reports strong Q3 growth: revenue up 22%, EBITDA surges 72%

The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year


Ajooni Biotech bags record Rs. 47.52 crore order
Biotech | February 10, 2026

Ajooni Biotech bags record Rs. 47.52 crore order

The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production


GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
News | February 10, 2026

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum


SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
News | February 10, 2026

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%